



General Assembly

January Session, 2009

**Substitute Bill No. 290**

\* SB00290APP 050609 \*

**AN ACT CONCERNING HEALTH INSURANCE COVERAGE FOR BONE MARROW TESTING.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective January 1, 2010*) (a) Subject to the  
2 provisions of subsection (b) of this section, each individual health  
3 insurance policy providing coverage of the type specified in  
4 subdivisions (1), (2), (4), (11) and (12) of section 38a-469 of the general  
5 statutes delivered, issued for delivery, amended, renewed or  
6 continued in this state on or after January 1, 2010, shall provide  
7 coverage for expenses arising from human leukocyte antigen testing,  
8 also referred to as histocompatibility locus antigen testing, for A, B and  
9 DR antigens for utilization in bone marrow transplantation.

10 (b) No such policy shall impose a coinsurance, copayment,  
11 deductible or other out-of-pocket expense for such testing in excess of  
12 twenty per cent of the cost for such testing per year. The provisions of  
13 this subsection shall not apply to a high deductible health plan as that  
14 term is used in subsection (f) of section 38a-520 of the general statutes.

15 (c) Such policy shall:

16 (1) Require that such testing be performed in a facility (A)  
17 accredited by the American Society for Histocompatibility and  
18 Immunogenetics, or its successor, and (B) certified under the Clinical  
19 Laboratory Improvement Act of 1967, 42 USC Section 263a, as  
20 amended from time to time; and

21 (2) Limit coverage to individuals who, at the time of such testing,  
22 complete and sign an informed consent form that also authorizes the  
23 results of the test to be used for participation in the National Marrow  
24 Donor Program.

25 (d) Such policy may limit such coverage to a lifetime maximum  
26 benefit of one testing.

27 Sec. 2. (NEW) (*Effective January 1, 2010*) (a) Subject to the provisions  
28 of subsection (b) of this section, each group health insurance policy  
29 providing coverage of the type specified in subdivisions (1), (2), (4),  
30 (11) and (12) of section 38a-469 of the general statutes delivered, issued  
31 for delivery, amended, renewed or continued in this state on or after  
32 January 1, 2010, shall provide coverage for expenses arising from  
33 human leukocyte antigen testing, also referred to as histocompatibility  
34 locus antigen testing, for A, B and DR antigens for utilization in bone  
35 marrow transplantation.

36 (b) No such policy shall impose a coinsurance, copayment,  
37 deductible or other out-of-pocket expense for such testing in excess of  
38 twenty per cent of the cost for such testing per year. The provisions of  
39 this subsection shall not apply to a high deductible health plan as that  
40 term is used in subsection (f) of section 38a-520 of the general statutes.

41 (c) Such policy shall:

42 (1) Require that such testing be performed in a facility (A)  
43 accredited by the American Society for Histocompatibility and  
44 Immunogenetics, or its successor, and (B) certified under the Clinical  
45 Laboratory Improvement Act of 1967, 42 USC Section 263a, as  
46 amended from time to time; and

47 (2) Limit coverage to individuals who, at the time of such testing,  
48 complete and sign an informed consent form that also authorizes the  
49 results of the test to be used for participation in the National Marrow  
50 Donor Program.

51 (d) Such policy may limit such coverage to a lifetime maximum  
52 benefit of one testing.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>January 1, 2010</i>	New section
Sec. 2	<i>January 1, 2010</i>	New section

**INS**      *Joint Favorable Subst.-LCO*

**APP**      *Joint Favorable*